Very interesting analysis and key points to note -
1. B-ABSSI which was the star product and with new class and new MOA was supposed to get special approval from fda and was supposed to come to market in 24 months -
Peak sales only 300 million and will come to market in 2020 - 6 years after successful P2. Sad
2. K is not coming to market till 2023 - not even sure it will remain relevant by that time or CTIX survive
3 P - as against some very high peak sales numbers thrown - not very huge
Everything is so far off and no stream of revenue in near future - Aspire is the funding source unless they are lucky to find a partner